Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A2 | P19784 | 8/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 8/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213582 | 0.95 | CSNK2A2 (0.42) | CSNK2A2CSNK2A1KDM4ERAB9AHDAC1 | |
| SCHEMBL211758 | 0.95 | CSNK2A2 (0.41) | CSNK2A2CSNK2A1KDM4ERAB9AALDH1A1 | |
| SCHEMBL212407 | 0.94 | CSNK2A2 (0.41) | CSNK2A2CSNK2A1RXFP1KDM4ERAB9A | |
| SCHEMBL215001 | 0.94 | CSNK2A2 (0.41) | CSNK2A2CSNK2A1RXFP1KDM4ERAB9A | |
| SCHEMBL2724041 | 0.94 | RXFP1 (0.40) | CSNK2A2CSNK2A1RXFP1KDM4ERAB9A | |
| SCHEMBL213027 | 0.93 | RAB9A (0.45) | CSNK2A2CSNK2A1RXFP1KDM4ERAB9A | |
| SCHEMBL212087 | 0.92 | CSNK2A2 (0.39) | CSNK2A2CSNK2A1RXFP1KDM4ERAB9A | |
| SCHEMBL212508 | 0.91 | KDM4E (0.42) | CSNK2A2CSNK2A1RXFP1KDM4ERAB9A | |
| SCHEMBL2725740 | 0.89 | CSNK2A2 (0.40) | CSNK2A2CSNK2A1RXFP1KDM4ERAB9A | |
| SCHEMBL2723939 | 0.88 | CSNK2A2 (0.39) | CSNK2A2CSNK2A1KDM4ERAB9AHDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8895582-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-11-25 | — | — | US | disclosed |
| US-8759374-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2013-02-28 | — | — | US | disclosed |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | QIAN XIANGPING (US) | 2012-05-31 | — | — | US | disclosed |
| US-8088793-B2 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INC. | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275537-A1 | Certain chemical entities, compositions, and methods | MYLK, MYH2, MYH10 | CSNK2A2 534/4885CSNK2A1 714/4885RXFP1 2101/4885 |
| US-20120135964-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CSNK2A2 534/4885CSNK2A1 714/4885RXFP1 2101/4885 |
| US-20130053348-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | MYLK, MYH2, MYH10 | CSNK2A2 534/4885CSNK2A1 714/4885RXFP1 2101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.